IVVD Stock Risk & Deep Value Analysis
Invivyd Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About IVVD Stock
We analyzed Invivyd Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran IVVD through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is IVVD Stock?
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
Competitive Risk
High
Execution Risk
High
Regulatory Risk
Medium
What Are the Red Flags for IVVD?
- ⚠
Disappointing VYD222 sales performance in Q4 2025 and Q1 2026.
- ⚠
Need for additional financing leading to significant shareholder dilution.
- ⚠
Emergence of new, highly resistant SARS-CoV-2 variants rendering VYD222 less effective.
- ⚠
Increased competition from new prophylactic treatments or improved vaccines.
Unlock IVVD Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Invivyd Inc (IVVD) Do?
Market Cap
$636.38M
Sector
Healthcare
Industry
Biotechnology
Employees
99
Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's pipeline includes PEMGARDA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate, which is in preclinical studies for the prevention or treatment of COVID-19; and Adintrevimab that is in phase 2/3 clinical trials for the prevention and treatment of COVID-19. It also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. The company has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
Visit Invivyd Inc WebsiteIs IVVD Stock Undervalued?
Unlock the full AI analysis for IVVD
Get the complete DVR score, risk analysis, and more
Does IVVD Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable
Moat Sources
2 Identified
The moat primarily stems from the intellectual property protecting VYD222 and its specific regulatory authorization for a critical unmet need. However, its durability is challenged by the evolving nature of the virus, requiring continuous R&D, and the potential for new entrants or superior treatments from larger pharmaceutical companies.
Moat Erosion Risks
- •Emergence of SARS-CoV-2 variants resistant to VYD222.
- •Competition from alternative prophylactic options or enhanced vaccines.
- •Expiration of key patents or challenges to IP.
IVVD Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive IVVD Stock Higher?
Near-Term (0-6 months)
- •Q4 2025 Earnings Report (Estimated late-March/early-April 2026) – Focus on VYD222 sales data and 2026 guidance.
- •Updates on VYD222 commercialization strategy and payer coverage improvements.
- •Clinical data updates for VYD222 against new SARS-CoV-2 variants.
Medium-Term (6-18 months)
- •Potential label expansion for VYD222 or new indications.
- •Progress of VYD721 (next-gen mAb) into clinical trials (Phase 1/2).
- •Strategic partnerships to enhance VYD222 distribution or market penetration.
Long-Term (18+ months)
- •Establishment of Invivyd as a leader in prophylactic mAb treatments for immunocompromised populations.
- •Development of a robust pipeline addressing evolving infectious disease threats.
- •Potential for VYD222 to become a standard of care for its target population.
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for IVVD?
- ✓
Acceleration in VYD222 quarterly sales figures.
- ✓
Improved gross margins and progress towards cash flow breakeven.
- ✓
Positive updates on VYD721 clinical trials or new pipeline assets.
- ✓
Successful and non-dilutive financing rounds, if necessary.
Bull Case Analysis
See what could go right with Premium
Compare IVVD to Similar Stocks
See how Invivyd Inc stacks up against related companies in our head-to-head analysis.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for IVVD (Invivyd Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
